70/100
✓ Peer-reviewed
alzhub usefulness score 70 out of 100.
·
JAMA
·
2002-02-01
These results suggest that frequent participation in cognitively stimulating activities is associated with reduced risk of AD. 5 key findings →
Design: cohort study
Participants: 111
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
This analysis of 2-year retrospective cohort studies of individuals diagnosed with COVID-19 showed that the increased incidence of mood and anxiety disorders was transient, with no overall excess of these diagnoses compared with other respiratory infections. 5 key findings →
Design: cohort study
Participants: 47
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
70/100
✓ Peer-reviewed
alzhub usefulness score 70 out of 100.
·
JAMA psychiatry
·
2017-07-01
Those reporting depressive symptoms in 1985 (mean follow-up, 27 years) did not have significantly increased risk for dementia (hazard ratio [HR], 1.21; 95% CI, 0.95-1.54) in Cox regression adjusted for sociodemographic covariates, health behaviors, and chronic conditions. 5 key findings →
Design: cohort study
Participants: 322
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Elderly people taking anticholinergic drugs had significant deficits in cognitive functioning and were highly likely to be classified as mildly cognitively impaired, although not at increased risk for dementia. 4 key findings →
Design: cohort study
Participants: 372
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Loneliness is associated with an increased risk of late-life dementia but not with its leading causes. 5 key findings →
Design: cohort study
Participants: 76
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
Neurology
·
2006-12-01
It has been assumed that each MCI subtype is associated with an increased risk for a particular type of dementia. 2 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Depressive symptoms were associated with increased risk of MCI, and this association was independent of underlying vascular disease. 5 key findings →
Design: longitudinal study
Participants: 2,220
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
Neurology
·
2008-03-01
Dementia is a key part of survival in Parkinson disease and must be planned for in services for this condition. 1 key finding →
Design: cohort study
Participants: 140
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We have previously performed detailed clinical and neuropsychological assessments in a community-based cohort of patients with newly diagnosed parkinsonism, and through analysis of a subcohort with idiopathic Parkinson's disease (PD), we have demonstrated that cognitive dysfunction occurs even at the time of PD diagnosis and is heterogeneous. 1 key finding →
Design: longitudinal study
Participants: 126
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA
·
1995-04-01
These data suggest the following: (1) patients with mild cognitive impairment can be clinically defined, (2) many members of this group progress to Alzheimer's disease, and (3) APOE epsilon 4 allele status appears to be a strong predictor of clinical progression. 2 key findings →
Design: longitudinal study
Participants: 66
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Nature aging
·
2023-05-18
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD) in clinical practice. 5 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
In multivariate analyses, baseline age, University of Pennsylvania Smell Inventory Test (UPSIT) scores, CSF amyloid - (Aβ 42 ) to t-tau ratio, and APOE status were associated with change in MoCA scores over time. 5 key findings →
Design: cohort study
Participants: 390
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Pulse pressure and pulse wave velocity, markers of arterial stiffness, have been associated with stroke, dementia, and lowered levels of cognitive function. 3 key findings →
Design: longitudinal study
Participants: 1,749
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Of 31 624 156 adults discharged from French hospitals between 2008 and 2013, 1 109 343 were diagnosed with dementia and were included in the analyses. 2 key findings →
Design: retrospective cohort
Participants: 156
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cognitive impairment without dementia is more prevalent in the United States than dementia, and its subtypes vary in prevalence and outcomes. 2 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cognitive impairment is associated with increased use of health services and increased mortality. 4 key findings →
Design: cohort study
Participants: 3,954
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Insulin resistance causes diminished glucose uptake in similar regions of the brain in Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2). 4 key findings →
Design: longitudinal study
Participants: 26
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA Network Open
·
2024-10-01
These findings indicate that AWV recipients had a timelier first MCI diagnosis than those who did not receive an AWV, but first ADRD diagnosis differed little. 5 key findings →
Design: cohort
Participants: 549,516
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Longitudinal clinical-pathological studies have increasingly recognized the importance of mixed pathologies (the coexistence of one or more neurodegenerative and cerebrovascular disease pathologies) as important factors in the development of Alzheimer's disease (AD) and other forms of dementia. 1 key finding →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Among older Medicare beneficiaries, incident AF is common and has remained relatively stable for more than a decade. 3 key findings →
Design: cohort study
Participants: 433,123
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
Stroke
·
2023-05-01
PSCI is common after stroke, especially in the first year, and ranges from mild to severe. 1 key finding →
Design: cohort study
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-center study assessing neuroimaging in diagnosis and longitudinal monitoring. 4 key findings →
Design: longitudinal study
Participants: 339
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
In this large cohort, exposure to air pollution, even at the relative low levels, was associated with higher dementia incidence. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Kaplan-Meier analysis showed that patients with IRBD who were α-synuclein negative had lower risk for developing Parkinson's disease or dementia with Lewy bodies at 2, 4, 6, 8, and 10 years of follow-up than patients with IRBD who were α-synuclein positive (log-rank test p=0·028; hazard ratio 0·143, 95% CI 0·019-1·063). 3 key findings →
Design: longitudinal study
Participants: 52
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
JAMA Network Open
·
2024-09-03
The mechanism of injury was a fall in 1 228 847 incidents (50.1%). 5 key findings →
Design: cohort
Participants: 2,453,655
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 31,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.